Who are Penehyclidine inhalation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Drug: ipratropium (AtroventTM), Bricanyl/Iprovent.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/penehyclidine-inhalation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Penehyclidine inhalation — Competitive Intelligence Brief

Penehyclidine inhalation (Penehyclidine inhalation) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic bronchodilator. Area: Respiratory/Pulmonology.

marketed Anticholinergic bronchodilator Muscarinic acetylcholine receptors (M1, M3) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Penehyclidine inhalation (Penehyclidine inhalation) — Peking University First Hospital. Penehyclidine is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce airway secretions and bronchospasm.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Penehyclidine inhalation TARGET	Penehyclidine inhalation	Peking University First Hospital	marketed	Anticholinergic bronchodilator	Muscarinic acetylcholine receptors (M1, M3)
Drug: ipratropium (AtroventTM)	Drug: ipratropium (AtroventTM)	AstraZeneca	marketed	Anticholinergic bronchodilator	M3 muscarinic acetylcholine receptor
Bricanyl/Iprovent	Bricanyl/Iprovent	University of Monastir	phase 3	Beta-2 adrenergic agonist (Bricanyl); Anticholinergic bronchodilator (Iprovent)	Beta-2 adrenergic receptor (Bricanyl); Muscarinic acetylcholine receptor (Iprovent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic bronchodilator class)

AstraZeneca · 1 drug in this class
Peking University First Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Penehyclidine inhalation — Competitive Intelligence Brief. https://druglandscape.com/ci/penehyclidine-inhalation. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab